Please ensure Javascript is enabled for purposes of website accessibility

Why Nektar Therapeutics Crashed 17.2% Today

By Todd Campbell – Updated Oct 22, 2018 at 5:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in the company are slipping as short-sellers call into question one of its most important clinical-stage drugs.

What happened

After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics(NKTR -6.54%) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today.

So what

In February, Bristol-Myers Squibb (BMY -1.12%) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo. In that deal, Bristol-Myers paid $1 billion for rights to 35% of NKTR-214's future profits, and $850 million for 8.3 million Nektar Therapeutics shares.

A person looking at a declining stock price chart holds his head with his hands.


Investor optimism for Nektar Therapeutics has waned since June, though, following the release of updated data for the two-drug combination at the annual American Society of Clinical Oncology (ASCO). Previously, a 64% overall response rate had reported in melanoma patients, but that response rate slipped to 50% after more patients were evaluated. The response rates of the two drugs in kidney cancer patients also slipped.

A pegylated formulation of IL-2, NKTR-214 is designed to last longer than recombinant IL-2, a cytokine that prompts the creation of lymphocytes that can battle cancer.

According to Plainview, "the clinical dose of NKTR-214 yields only 7-20% of the active AUC (drug exposure) of a standard cycle of IL-2." Furthermore, Plainview maintains that lackluster efficacy as a monotherapy in phase 1 trials doesn't bode well for the combination trial panning out. Plainview's report states that NKTR-214's "thesis and clinical data are nearly identical to the now-disproven IDO inhibitor story, and the notion that a failed monotherapy will add statistically significant value as part of a combination therapy has never worked in practice."

Now what

Only time will tell if NKTR-214 and Opdivo combination therapy can elicit response rates in large, late-stage studies that allow it to secure an FDA OK. So far, Bristol-Myers Squibb isn't backing away from the drug. A phase 3 study in advanced melanoma began in the third quarter, and phase 3 trials are also being planned in kidney cancer.

Nektar Therapeutics has had 10 abstracts accepted for presentation at next month's 2018 Society for Immunotherapy of Cancer (SITC) meeting, including an oral presentation entitled, "Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma." Investors may want to see how these abstracts are received before buying shares. 

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
$3.00 (-6.54%) $0.21
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$71.25 (-1.12%) $0.81
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$328.35 (-1.80%) $-6.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.